Insights

Insights From Our Experts

Articles

Are We Transforming In The Right Way?

Why Product Launches Can’t Be Distracted By Empty Promises. We can all agree that innovations in therapeutic development have advanced beyond traditional product launch strategies and service models. In every step of the product lifecycle, we…

Power in numbers: Seven national plans manage almost half of the medical lives in the U.S.

Market Access Macrotrends provides  insight for you to stay on top of market access trends, anticipate how the healthcare landscape is evolving, and provide strategic guidance for your organization. Market Access Macrotrends answers your questions about changes in…

A More Trusting Relationship Can Lead to a Better Patient Experience

In this September feature, PM360 dives into what it takes to create relationships and experiences with and for patients. Considering that patients want more authentic interactions when dealing with life sciences companies, Jenny Sparano, director of…

Driving the Commercialization of Regenerative Medicine

With more than 7,000 distinct types of rare and genetic diseases and 400+ million individuals suffering from a rare disease, regenerative medicine holds the hope for a cure – transforming healthcare by revolutionizing patient care from…

Technology + Compliance = Improved Models of Care in Life Science Services

Compliance is a broad and extremely important area in almost every industry and more so in life sciences as it directly and indirectly impacts patient lives. Because the life science industry is continuously evolving, we are…

Pushing Your Frontline Into A New Frontier

The pharmaceutical industry is complex. A litany of companies and brands are competing for top-of-mind usage with clinicians, a cohesive partnership with payers, and active engagement with patients. It’s hard enough to bring a drug to…

white paper-insights
340B Drug Pricing: Challenges and Best Practices

Enacted in 1992, the 340B Drug Pricing Program was intended to stretch scarce federal resources and services to more eligible patients. Despite achieving this goal in many respects, it has  also become notoriously difficult to manage…

Ramifications of “Medicare for All” and Implications for Clinical Pathways

As the Medicare for All (M4A) debate continues into 2020, clinical pathway organizations, payers, health systems, providers, and patients will all play a role in shaping future policies around patient access and reimbursement. While it is…

Insurance and Benefit Design

Insurance and Benefits Design provides insight on changes in insurance and benefit design in the next three years so you can anticipate the evolving access opportunities and risks for your company’s brands. Insurance and Benefit Design…

IDN Profiles

IDN Profiles provides insight on the size, structure, and business strategies of the leading IDNs so you can develop business and account plans. IDN Profiles answers your questions so you can develop business and account plans.…